Abstract
Drugs acting upon the benzodiazepine binding sites of the GABAA receptor complex constitute one of the most widely used class of psychotropic agents. These drugs increase the sensitivity of the GABAA receptor to its natural agonist, γ-aminobutyric acid (GABA). This allosteric facilitation of GABAergic neurotransmission has found clinical application in the treatment of a large number of disorders [1–3]. These applications are based on the sedative, anxiolytic, anticonvulsant and myorelaxant activities of benzodiazepine receptor agonists. Moreover, these drugs also display untoward effects such as memory disruption, and after chronic treatment, induction of tolerance and dependence. These pleitropic actions constitute one of the most important drawback of benzodiazepines. For this reason, much research has tried to dissociate the effects responsible for the therapeutic activity from those considered as secondary. For example, to dissociate anxiolytic from sedative effects, or hypnotic effects from memory impairment or myorelaxant activities, and also to avoid the induction of tolerance or dependence.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Squires RF, Braestrup C. Benzodiazepine receptors in rat brain. Nature 1977; 266:732–34.
Puia G, Vicini S, Seeburg PH, Costa E. Differences in the action of benzodiazepines and neurosteroids on recombinant γ-aminobutyric acid receptors. In: Barnard EA, Costa, E eds. Transmitter Amino Acid Receptors: Structures, Transduction and Models for Drug Development. New York, Thieme. 1991; 177–83.
Haefely W, Kuksar A, Mohler H, Pieri L, Pole P, Schaffner R. Possible involvement of GABA in the central actions of the benzodiazepines. Adv Biochem Psychopharmacol 1975;14:131–49.
Olsen RW, Tobin AJ. Molecular biology of GABAA receptors. FASEB J. 1990;4:1469–80.
Dunn SMJ, Bateson AN, Martin LL. Molecular neurobiology of the GABAA receptor. Int. Rev. Neurobiol. 1994;36:51–96.
Benavides J, Peny B, Ruano D, Vitorica J, Scatton B. Comparative autoradiographic distribution of central ω (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 1993;604:240–50.
Dennis T, Dubois A, Benavides J, Scatton B. Distribution of central ω1 (benzodiazepine1) and ω2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]flunitrazepam and the ω1) selective ligand [3H] zolpidem. J Pharmacol Exp Ther 1988;247:309–22.
Pritchett DB, Luddens H, Seeburg PH. Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science 1989;245:1389–92.
Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992;12:1040–60.
Laurie DJ, Seeburg PH, Wisden W. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J Neurosci 1992;12:1063–76.
Sanger D J, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355–72.
Depoortere H, Decobert M, Riou-Merle F, Granger P. Pharmaco-EEG profile of zolpidem: an imidazopyridine hypnotic agent. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press 1988;81–96.
Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G. Zolpidem, a novel non-benzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986;237:649–58.
Niddam R, Dubois A, Scatton B, Arbilla S, Langer SZ. Autoradiographic localization of 3H-zolpidem binding sites in the rat central nervous system. Comparison with the distribution of 3H-flunitrazepam binding sites, J. Neurochem., 1987;49:890–99.
Ruano D, Vizuete M, Cano J, Machado DA, Vitorica J, Heterogeneity in the allosteric interaction between the GABAA receptor and the benzodiazepine receptor in the rat nervous system, J. Neurochem, 1992;58:485–93.
Dana C, Peny B, Schoemaker H, Benavides J, Autoradiographic distribution of ω (benzodiazepine) modulatory site subtypes in the primate brain. Canadian J. Physiol. Pharmacol. 1994;72,S 1:337.
Pritchett DB, Seeburg PH. γ-Aminobutyric acidA receptor α5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 1990;54:1802–4.
Faure-Halley C, Graham D, Arbilla S, Langer, S Z. Expression and properties of recombinant α1β2γ2 and α5β2γ2 forms of the rat GABAA receptor. Eur J Pharmacol, Mol Pharmacol Sect, 246:283–87.
Lueddens H, Seeburg PH, Korpi ER. Impact of β and γ variants on ligand-binding properties of γ-aminobutyric acid type A receptors. Mol Pharmacol 1994;45:810–14.
Wafford KA, Bain CJ, Whiting PJ, Kemp J. Functional comparison of the role of γ subunits in recombinant human γ-aminobutyric acidA/benzodiazepine receptors. Mol Pharmacol 44:437–42
Puia G, Vicini S, Seeburg PH, Costa E. Differences in the action of benzodiazepines and neurosteroids on recombinant gamma-aminobutyric acid receptors. Barnard EA, Costa E eds. Transmitter Amino Acid Receptors: Structures, Transduction and Models for Drug Development, 177–83
Perrault G, Morel E, Sanger DJ, Zivkovic B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic Zolpidem. J Pharmacol Exp Ther 1992;263:298–303.
Depoortere H, Granger P, Biton B, Avenet P, Faure C, Graham D, Langer SZ, Scatton B. Functional and pharmacological properties of α1β2γ2, α3β2γ2 and α5β2γ2 subtypes of GABAA receptors transiently expressed in HEK 293 cells. Canadian J Physiol Pharmacol 1994;72,S 1:338.
Benavides J, Peny B, Dubois A, Perrault G, Morel E, Zivkovic B, Scatton B. In vivo interaction of zolpidem with central benzodiazepine binding sites (as labelled by 3H-Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the ω1, (BZD1) subtype. J Pharmacol Exp Ther 1988;245:1033–1041.
Benavides J, Peny B, Durand A, Arbilla S, Scatton B. Comparative in vivo and in vitro regional selectivity of central ω (BZ) modulatory site ligands as displacers of [3H]flumazenil binding in the rat CNS. J Pharmacol Exp Ther 1992;263:884–96.
Benavides J, Depoortere H, Sanger D, Perrault G, Arbilla S, Langer SZ, Zivkovic B, Scatton B. Un domaine specifique (site ω1,) du récepteur GABAA pourrait être impliqué dans les effets hypnotiques du zolpidem. L’Encéphale 1990;XVI: 13–22.
Sauvanet JP, Maarek L, Roger M, Renaudin J, Louvel E, Orofiamma B. Open long-term trials with zolpidem in insomnia. In: Sauvanet JP, Langer SZ, Morselli PL eds. Imidazopyridines in sleep disorders. New York: Raven Press 1988;339–49.
Schlich D, L’Héritier C, Coquelin JP, Attali P. Long-term treatment of insomnia with Zolpidem: a multicentre general practitioner study of 107 patients. J. of Internal. Med. Res. 1991;19:271–79.
Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiat. 1994;27:166–75.
Nicholson A, Pascoe P. Hypnotic activity of an imidazopyridine (zolpidem). Br. J. Clin. Pharmacol. 1986;21:205–11
Balkin TJ, O’Donnell VM, Wesensten N, McCann U, Belenky G. Comparison of the daytime sleep and performance effects of Zolpidem versus triazolam. Psychopharmacology 1992; 107:83–88.
Pappata S, Samson Y, Chavoix C, Prenant C, Maziere M, Baron JC. Regional specific binding of 11C-Ro15-1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J Cereb Blood Flow 1988;8:304–13.
Samson Y, Hantraye P, Baron JC, Soussaline F, Comar D, Maziere M. Kinetics and displacement of 11C-Rol5-1788 a benzodiazepine antagonist studied in human brain in vivo by positron emission tomography. Eur J Pharmacol 1985; 110:247–51.
Abadie P, Baron JC, Bisserbe JC, Boulenger JP, Rioux P, Travere JM, Barre L, Petit-Taboue MC, Zarifian E. Central benzodiazepine receptors in human brain: estimation of regional Bmax and Kd values with positron emission tomography. Eur J Pharmacol 1992;213:107–15.
Durand A, Thenot JP, Bianchetti G, Morselli PL. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drugs Metabol Rev 1992;24:239–66.
Abadie P, Rioux P, Legangneux E, Scatton B, Zariafian E, Bane L. In vivo interaction of zolpidem with the central benzodiazepine receptors in humans: a positron emission tomography study with 11C-flumazenil. Neuropsychopharmacol. 1994;10,3S:112.
Ito K, Yamada Y, Nakamura K, Sawada Y, Iga T. Classification of benzodiazepine hypnotics in humans based on receptor occupancy theory. J. Pharmacokinetics Biopharmaceutics 1993;21:31–41.
Lassen NA. Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection or radioactive tracers. J Cereb Blood Flow 1992;12:709–16.
Pauli S, Farde L, Halldin L, Sedvall G. Occupancy of the central benzodiazepine receptors during benzodiazepine treatment determined by PET. Eur. J. Neuropsychopharmacol 1991; 1:229–31.
Videbaek C, Friberg L, Holm S, Wammen S, Foged C, Andersen JV, Dalgaard L, Lassen NA. Benzodiazepine receptor equilibrium constants for flumazenil and midazolam determined in humans with the single photon emission compputer tomography tracer 125I- iomazenil. Eur J Pharmacol 1993;249:43–51
Hantraye Ph, Chavoix C, Guibert B, Fukuda H, Brouillet E, Dodd RH, Prenant C, Crouzel M, Naquet R, Maziere M. Benzodiazepine receptors studied in living primates by positron emission tomography: inverse agonist interactions. Eur J Pharmacol 1987;138:239–47.
Hantraye Ph, Brouillet E, Fukuda H, Chavoix C, Guibert B, Dodd RH, Prenant C, Crouzel M, Naquet R, Maziere M. Benzodiazepine receptors studied in living primates by positron emission tomography: antagonist interactions. Eur J Pharmacol 1988;153:25–32.
De la Sayette V, Chavoix C, Brouillet E, Hantraye P, Kunimoto M, Khalili-Varasteh M, Guibert B, Prenant C, Maziere M. In vivo benzodiazepine receptor occupancy by CL 218,872 visualized by positron emission tomography in the brain of the living baboon: modulation by GABAergic transmission an relation with anticonvulsant activity. Exp Brain Res 1991;83:397–402.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Benavides, J., Abadie, P., Baron, J.C., Scatton, B. (1995). Comparative In vivo and In vitro Selectivity of Zolpidem for ω (Benzodiazepine) Modulatory Site Subtypes. In: Comar, D. (eds) PET for Drug Development and Evaluation. Developments in Nuclear Medicine, vol 26. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0429-6_10
Download citation
DOI: https://doi.org/10.1007/978-94-011-0429-6_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4191-1
Online ISBN: 978-94-011-0429-6
eBook Packages: Springer Book Archive